Search

Displaying results 2301 - 2310 of 10000 in total
  1. Drug

    Lumateperone

    go.drugbank.com/drugs/DB06077
    ApprovedInvestigational

    [A189093] Lumateperone is a newly approved 2nd generation antipsychotic currently indicated for the treatment of schizophrenia. … [A189093] Further, not only is the new antipsychotic selective for dopamine (D2) receptors in the mesolimbic and mesocortical brain regions, but it also has minimal off-target activity.

  2. Drug

    Vimseltinib

    go.drugbank.com/drugs/DB17520
    ApprovedInvestigational

    in a lower risk of off-target effects, including hepatotoxicity. … [L52230,A265035] Vimseltinib - under the brand name Romvimza - was approved by the FDA in February 2025 for the treatment of tenosynovial giant cell tumours for which surgical resection is not appropriate

  3. Drug

    SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer (B.1.351-B.1.1.7 strains)

    go.drugbank.com/drugs/DB18705
    Approved

    [L48902,L48907] Bimervax was issued marketing authorization in the EU in March 2023 for use as a booster dose in patients who have previously received an mRNA COVID-19 vaccine.[L48907] … Bimervax is an adjuvanted non-mRNA COVID-19 vaccine utilizing a SARS-CoV-2 recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer.

  4. Drug

    Sulfadiazine

    go.drugbank.com/drugs/DB00359
    ApprovedInvestigationalVet approved

    One of the short-acting sulfonamides used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.

    Synonyms: N(1)-2-Pyrimidylsulfanilamide, N(1)-2-PyrimidinylsulfanilamideCategories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  5. Drug

    Aprepitant

    go.drugbank.com/drugs/DB00673
    ApprovedInvestigational

    Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting … Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors.

    Products: APREPITANT AL 80MG HKP, APREPITANT AL 125MG HKP
  6. Drug

    Nitrofural

    go.drugbank.com/drugs/DB00336
    ApprovedVet approvedWithdrawn

    Nitrofural or nitrofurazone is a topical anti-infective agent effective against gram-negative and gram-positive bacteria. It is used for superficial wounds, burns, ulcers, and skin infections. … Nitrofural has also been administered orally in the treatment of trypanosomiasis.

  7. Drug

    Deuruxolitinib

    go.drugbank.com/drugs/DB18847
    ApprovedInvestigational

    [A264113] On July 26, 2024, deuruxolitinib was approved by the FDA for the treatment of severe alopecia areata. … Deuruxolitinib is a deuterated form of [ruxolitinib] that selectively inhibits Janus kinases (JAK) JAK1 and JAK2.

  8. Drug

    Human interferon beta

    go.drugbank.com/drugs/DB14999
    ApprovedInvestigational

    It is therefore a potential drug candidate for SARS-CoV-2 based on viral genetic similarity.[A191733,L12012] … [A191784] Interferon beta is currently being studied as a possible treatment for COVID-19, which results from infection with the novel 2019 SARS-CoV-2 virus.

    Categories: Experimental Unapproved Treatments for COVID-19
  9. Drug

    Conjugated estrogens

    go.drugbank.com/drugs/DB00286
    ApprovedInvestigational

    [T475] The conjugated estrogen mixture was approved for marketing in US in 1942 based on the efficacy against certain conditions. … It also presents a large number of unidentified molecules with weak estrogenic activity as well as non-human molecules when it is obtained from pregnant mares urine.

  10. Drug

    Corifollitropin alfa

    go.drugbank.com/drugs/DB09066
    ApprovedInvestigational

    In July 2014, Merck announced the receipt of a Complete Response Letter (CRL) from the U.S. FDA for its New Drug Application for this drug. … Corifollitropin alfa, also known as _Elonva_ is used in women undergoing fertility treatment to stimulate the development of more than one mature egg (oocyte) at a time in the ovaries.

    Products: Elonva Solution for Injection 150mcg/0.5ml, Elonva Solution for Injection 100mcg/0.5ml